Brand-money forensics · from the 250-topic plan
Anatomy of a winning GLP-1 appeal: turning a denial letter inside out
A prior-authorization denial is a first offer, and appeals overturn a meaningful share of them — but only when the appeal answers the denial's actual reason instead of pleading generally. This teardown maps the four denial species (not-covered, criteria-not-met, step-therapy, quantity/dose), the five-part anatomy of a letter that wins (patient facts → criteria mapping → evidence citations → prior-attempt record → physician necessity), the deadlines that forfeit rights silently, and the external-review escalation most people never use. Read your denial letter first; it contains the appeal's outline.
Read the denial: the four species
Not covered (benefit exclusion): the plan excludes weight-management drugs categorically — the hardest species, appealed on comorbidity reframing (the request isn't cosmetic; it's diabetes prevention, apnea treatment, cardiovascular risk) or fought at open enrollment, not in letters. Criteria not met: the workhorse species — the plan covers the drug but claims your chart misses a threshold (BMI documentation, comorbidity, visit history). Almost always a documentation problem wearing a medical costume. Step therapy: "try X first" — appealed by documenting X was tried, failed, or is contraindicated. Quantity/dose: the plan balks at a dose or fill pattern — appealed with the label's own titration schedule. Every species names its counter; the letter that ignores the species loses politely.
The five-part letter
One — the header facts: member ID, claim number, denial date, the exact drug and dose, and the sentence "This is a formal appeal of the denial dated ___." Bureaucracies file what's labeled. Two — criteria mapping: quote the plan's own PA criteria (they're published or obtainable on request) and answer each element line-by-line with chart citations — BMI on date X, comorbidity diagnosed date Y, six months of documented attempts. The letter that mirrors the checklist gets approved by the checklist. Three — the evidence paragraph (below). Four — the prior-attempt record: named programs, dates, outcomes; step-therapy species live and die here. Five — physician necessity: the prescriber's letter, on letterhead, stating clinical judgment that this therapy is medically necessary for this patient and alternatives are inadequate — the single highest-yield attachment in the file.
The evidence paragraph, pre-drafted
Plans respond to their own language — outcomes and cost-offsets — so cite accordingly: SURMOUNT-1's weight and threshold results with the ~94% three-year diabetes-prevention extension; STEP 1 plus SELECT's major-cardiovascular-event reduction for semaglutide; SURMOUNT-OSA where apnea is charted; the withdrawal trials to argue maintenance coverage when a plan tries to sunset an approval mid-success. One paragraph, studies named, tied to this patient's charted conditions — evidence recited without mapping is wallpaper.
Deadlines and levels
The denial letter states your internal-appeal window — commonly 180 days, sometimes less — and miss it and every argument above expires unheard. Internal appeals often run two levels; urgent-care expedited tracks exist when delay threatens health. Log everything: dates, names, reference numbers, and send methods that prove receipt. The appeal is litigation-shaped even when it's friendly; build the record like it matters, because at the next level it does.
External review: the level people forget
Exhaust internal appeals and most plans owe you independent external review — a reviewer outside the insurer, binding on the plan, free or near-free to you, with its own deadline printed in the final denial. External reviewers apply medical evidence over plan habit, which is exactly the terrain the evidence paragraph was built for. While any of this runs: the card tiers bridge commercially insured patients, and the cash lanes — $349-class vials or the audited $119–$139 floor — price the fallback so the appeal is leverage, not hostage-taking. The cash fallback, audited ↗
FAQ
Are GLP-1 insurance denials worth appealing?
Frequently — appeals overturn a meaningful share, especially criteria-not-met and step-therapy denials answered with line-by-line documentation plus a physician necessity letter.
What should a GLP-1 appeal letter include?
Header facts and the formal-appeal sentence, the plan's own criteria answered element-by-element with chart citations, named trial evidence mapped to your conditions, the prior-attempt record, and a prescriber necessity letter.
What if my plan excludes weight-loss drugs entirely?
Category exclusions are the hardest species — reframe on charted comorbidities (diabetes prevention, apnea, cardiovascular risk) where indications allow, and fight the exclusion at open enrollment.
What is external review?
An independent, binding review outside the insurer available after internal appeals exhaust — deadline printed in the final denial, and the level where evidence beats plan habit.
Sources
- ACA internal-appeal and external-review framework; plan PA criteria documents.
- SURMOUNT-1 (+3-year extension), STEP 1, SELECT, SURMOUNT-OSA, SURMOUNT-4 — the citable evidence set.
- Manufacturer coverage-support resources; card terms for bridge pricing.